IBI397 + rituximab

IBI397 + rituximab is a combination of two monoclonal antibodies intended for oncology and immunotherapy applications. **IBI397** (also known as AL008) is a monoclonal antibody that acts as an inhibitor of signal-regulatory protein alpha (SIRPα), a target involved in the "don't eat me" signaling pathway that allows cancer cells to evade immune destruction. By blocking SIRPα, IBI397 aims to enhance macrophage-mediated phagocytosis of tumor cells. It was initially developed by Alector and reached Phase 1 clinical trials for advanced cancers but has since been discontinued[6]. **Rituximab** is a chimeric murine/human monoclonal antibody targeting CD20, an antigen expressed on B lymphocytes. It induces cell lysis through complement-dependent cytotoxicity and antibody-dependent cell-mediated cytotoxicity, leading to depletion of B cells. Rituximab is approved for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis (in combination with methotrexate), granulomatosis with polyangiitis, microscopic polyangiitis, and pemphigus vulgaris[1][2][4]. The rationale for combining these agents would be to simultaneously deplete B cells via anti-CD20 activity while enhancing innate immune clearance through SIRPα inhibition.

Other names

IBI 397IBI397IBI-397